Ustekinumab — clinical trials using this drug

Public-registry trials using Ustekinumab that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.

Ustekinumab appears in 1 registered trial Eichor's radar has found, sponsored by MedDerm Associates, the most recent registered as Phase 3, with a planned enrollment of 15. Registered timeline: 2012–2017. The registry holds 2,534 registered studies for Psoriasis.

Trial	Sponsor	Condition	Phase	Sites
Study to Evaluate Broadlumab vs Placebo and Ustekinumab	MedDerm Associates	Psoriasis	PHASE3	1

About this study

Study to Evaluate Broadlumab vs Placebo and Ustekinumab

Status	Terminated · planned start 2012-08
Primary completion	2017-06
Enrollment target	15 participants
Design	Randomized · Single Group · Phase 3 · 4 arms
Who it enrolls	All sexes · 18 Years and older — full criteria are on the study record
Locations	1 listed in United States

All fields verbatim from the ClinicalTrials.gov record for NCT02786732.

Origin & regulatory history

First FDA approval	STELARA — September 2009 (application BLA125261, currently held by CENTOCOR ORTHO BIOTECH INC)
Approval timeline	STELARA 2009 (CENTOCOR ORTHO BIOTECH INC) → WEZLANA 2023 (AMGEN INC) → SELARSDI 2024 (ALVOTECH USA INC) → PYZCHIVA 2024 (SAMSUNG BIOEPIS CO LTD) → OTULFI 2024 (FRESENIUS KABI USA) → IMULDOSA 2024 (ACCORD BIOPHARMA INC.) → YESINTEK 2024 (BIOCON BIOLOGICS INC) → STEQEYMA 2024 (CELLTRION, INC.) → +1 more brands
Also known as	STELARA · WEZLANA · SELARSDI · PYZCHIVA · OTULFI · IMULDOSA · YESINTEK · STEQEYMA · STARJEMZA
Approved applications	12 — a multi-source (generic) drug
Forms & routes	Injectable · Injection, Subcutaneous, Intravenous, Intravenous, Subcutaneous
Registry-wide use	265 registered studies all-time · 41 currently recruiting

Sources: FDA Drugs@FDA and ClinicalTrials.gov, public records. The application holder shown is the current holder, which may differ from the original developer.

Psoriasis drug landscape

The public registry holds 2,534 registered studies for Psoriasis. Compounds appearing across the 200 most recently updated registry entries:

Placebo ×49 Guselkumab ×17 bimekizumab ×12 Deucravacitinib ×12 JNJ-77242113 ×8 Zasocitinib ×8 Methotrexate ×7 Apremilast ×6 Risankizumab ×6 Tirzepatide ×6 Adalimumab ×5 Ixekizumab ×5 Tofacitinib ×4 Envudeucitinib ×3 Etanercept ×3 HPP737 ×3 Secukinumab ×3 Sonelokimab ×3 Spesolimab ×3 Azathioprine ×2 Certolizumab ×2 Cyclosporine ×2 Deucravacitinib Matching Placebo ×2 Diet ×2 Golimumab ×2 HPP737 and placebo ×2 Hydroxychloroquine ×2 Icotrokinra ×2 Infliximab ×2

Free site-risk snapshot for any of these trials

Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Related drugs & trials

Trialed alongside

Other Psoriasis drugs

← Eichor home · All tracked trials · Psoriasis studies · Weekly briefs

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →